Archive for the ‘drug design’ Category
The timing was tight, but Sergio Gonzalez had done it. Gonzalez, a postdoctoral researcher at the Institute for Neurosciences of Montpellier (INSERM) in France, had a paper accepted in a top journal by the end of 2015, just in time to apply for a small number of highly sought-after permanent research positions that open up in France each year.
If Gonzalez had missed the January deadline for this system of advancement, known as concours, he would have had to wait until the following cycle to apply.
Once his paper was accepted by the Journal of Clinical Investigation, Gonzalez could breathe a sigh of relief. He began being invited to interviews. But then, a comment showed up at PubPeer.
Pfizer has retracted a paper by a former employee who was fired after the company discovered she had been doctoring data.
The retraction, in Molecular Cancer Research, is the third of five papers Pfizer asked to retract, after an investigation discovered they contained duplicated images. The papers have been discussed on PubPeer, which is also mentioned in the latest retraction notice.
As a result of the investigation, Pfizer terminated the employment of Min-Jean Yin, the last author on the newly retracted paper.
According to the notice, Yin and five of her co-authors agreed to the retraction:
Last March, a PhD student at Harvard filed a misconduct allegation against his mentor, a prominent stem cell researcher. Three months later, he was taken from his home by police in the middle of the night for a forced psychiatric evaluation.
How did this happen? Read the rest of this entry »
Last year, Pfizer fired one of its scientists following an investigation that ended with requests for retraction of five of her studies. Now, two of the five papers, which were first flagged on PubPeer, have been retracted.
One notice cites the Pfizer investigation, which found that cancer researcher Min-Jean Yin had included duplicated images in all five papers. Yin is the last author on both retracted papers.
Here’s the first notice from Clinical Cancer Research, which says most or all of the questioned images appear to be duplicates, and Pfizer — who sponsored the study and requested the retraction — can’t find the originals:
Read the rest of this entry »
Researchers have agreed to pull a 2015 study exploring whether a plant extract can safeguard tanners from ultraviolet exposure after not obtaining formal approval from an ethics committee.
According to the first author, the problem lay in a misunderstanding – when they originally applied for approval six years ago, the researchers believed they didn’t need to go through a formal approval process, since the compound was commercially available without a prescription. Once they realized their mistake, they chose to retract the paper.
Here’s the retraction note for “Oral Polypodium leucomotos increases the anti-inflammatory and melanogenic responses of the skin to different modalities of sun exposures: a pilot study,” published in Photodermatology Photoimmunology & Photomedicine. Read the rest of this entry »
The group lost two papers in 2015 for the same reason, following a misconduct investigation at Oita University in Japan. Last year, the same group notched another retraction, and pegged the responsibility for the problematic figures on first author Satoshi Hagiwara.
Now, the group has published a fourth retraction in the European Journal of Pharmacology; the latest notice doesn’t identify a culprit. All four retracted papers list Hagiwara as first author.
A biologist at the University of Georgia has lost a paper after an investigation revealed she had tampered with three images.
In 2014, Azza El-Remessy notched three retractions for a series of image errors. Now, a fourth retraction notice, and an expression of concern, explain there has been an investigation into her work. The investigation — conducted by two Georgia institutions, along with the Charlie Norwood Veterans Affairs Medical Center, where El-Remessy has additional appointments — has found evidence of misconduct.
The head of the U.S. Food and Drug Administration (FDA) has called for the retraction of a study about a drug that the agency itself approved earlier this week, despite senior staff opposing the approval.
On September 19, the FDA okayed eteplirsen to treat Duchenne muscular dystrophy (DMD), a rare genetic disorder that results in muscle degeneration and premature death. Several of its top officials disagreed with the drug’s approval, questioning how beneficial it will be for patients, as Forbes, MedPage Today and others reported.
In a lengthy report Commissioner Robert Califf sent to senior FDA officials on September 16 — that was made public on September 19 — he called for the retraction of a 2013 study published in Annals of Neurology funded by the seller of eteplirsen, which showed beneficial effects of the drug in DMD patients. Califf writes in the report:
Last year, we reported on an investigation by the University of Colorado Denver into the research of Rajendra Kadam, which recommended retracting 10 papers. The report also flagged eight additional papers co-authored by Kadam whose data could not be validated, raising “concerns as to the scientific validity and integrity” of the material. A few months later, we reported on some of the notices — four retractions and an EOC — that had begun to appear for Kadam’s manuscripts.
We’ve since discovered more notices, bringing his total to seven retractions and three EOCs.
Kadam was once a prominent member in the lab of Uday Kompella, and often referred to by colleagues as the “golden boy,” according to the institution’s report. In 2012, he won a graduate student symposium award from the American Association of Pharmaceutical Scientists.
A University of Colorado Denver spokesperson told Retraction Watch: Read the rest of this entry »
A pharmacology researcher at Ohio State University has added his seventh retraction, four years after a finding of misconduct by the U.S. Office of Integrity (ORI).
falsified and/or fabricated Western blots in eighteen (18) figures and in six (6) published papers.
In 2012, the ORI finding, which resulted in a three-year funding ban (that is now complete), recommended that Elton retract all six papers, one of which had already been retracted at the time of the report.
Four years later, the last of the six papers flagged by the ORI has finally been retracted by Molecular and Cellular Endocrinology.